Thrombocytopenia associated with the use of GPIIb/IIIa inhibitors: position paper of the ISTH working group on thrombocytopenia and GPIIb/IIIa inhibitors

被引：49

作者：

Aster, RH

Curtis, BR

Bougie, DW

Dunkley, S

Greinacher, A

Warkentin, TE

Chong, BH

机构：

[1] Blood Ctr SE Wisconsin Inc, Blood Res Inst, Milwaukee, WI 53201 USA

[2] St George Hosp, Dept Med, Kogarah, NSW, Australia

[3] McMaster Univ, Dept Med & Mol Pathol, Hamilton, ON, Canada

[4] Univ Greifswald, Dept Immunol & Transfus Med, Greifswald, Germany

[5] Royal Prince Alfred Hosp, Haemophilia & Thrombosis Unit, Sydney, NSW, Australia

[6] Med Coll Wisconsin, Dept Med, Milwaukee, WI 53226 USA

来源：

JOURNAL OF THROMBOSIS AND HAEMOSTASIS | 2006年 / 4卷 / 03期

关键词：

D O I：

10.1111/j.1538-7836.2006.01829.x

中图分类号：

R5 [内科学];

学科分类号：

1002 ; 100201 ;

摘要：

[No abstract available]

引用

页码：678 / 679

页数：2

共 14 条

[1] Immune thrombocytopenia caused by glycoprotein IIb/IIIa inhibitors [J].

Aster, RH .

CHEST, 2005, 127 (02) :53S-59S

[2] Thrombocytopenia resulting from sensitivity to GPIIb-IIIa inhibitors [J].

Aster, RH ;

Curtis, BR ;

Bougie, DW .

SEMINARS IN THROMBOSIS AND HEMOSTASIS, 2004, 30 (05) :569-577

[3] Occurrence and clinical significance of thrombocytopenia in a population undergoing high-risk percutaneous coronary revascularization [J].

Berkowitz, SD ;

Sane, DC ;

Sigmon, KN ;

Shavender, JH ;

Harrington, RA ;

Tcheng, JE ;

Topol, EJ ;

Califf, RM .

JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY, 1998, 32 (02) :311-319

[4] Evidence that thrombocytopenia observed in humans treated with orally bioavailable glycoprotein IIb/IIIa antagonists is immune mediated [J].

Billheimer, JT ;

Dicker, IB ;

Wynn, R ;

Bradley, JD ;

Cromley, DA ;

Godonis, HE ;

Grimminger, LC ;

He, BK ;

Kieras, CJ ;

Pedicord, DL ;

Spitz, SM ;

Thomas, BE ;

Zolotarjova, NI ;

Gorko, MA ;

Hollis, GF ;

Daly, RN ;

Stern, AM ;

Seiffert, D .

BLOOD, 2002, 99 (10) :3540-3546

[5] Delayed tirofiban-induced thrombocytopenia: two case reports [J].

Bosco, A ;

Kidson-Gerber, G ;

Dunkley, S .

JOURNAL OF THROMBOSIS AND HAEMOSTASIS, 2005, 3 (05) :1109-1110

[6] Acute thrombocytopenia after treatment with tirofiban or eptifibatide is associated with antibodies specific for ligand-occupied GPIIb/IIIa [J].

Bougie, DW ;

Wilker, PR ;

Wuitschick, ED ;

Curtis, BR ;

Malik, M ;

Levine, S ;

Lind, RN ;

Pereira, J ;

Aster, RH .

BLOOD, 2002, 100 (06) :2071-2076

[7] Eptifibatide-associated acute, profound thrombocytopenia [J].

Coons, JC ;

Barcelona, RA ;

Freedy, T ;

Hagerty, MF .

ANNALS OF PHARMACOTHERAPY, 2005, 39 (02) :368-372

[8] Delayed thrombocytopenia after treatment with abciximab: a distinct clinical entity associated with the immune response to the drug [J].

Curtis, BR ;

Divgi, A ;

Garritty, M ;

Aster, RH .

JOURNAL OF THROMBOSIS AND HAEMOSTASIS, 2004, 2 (06) :985-992

[9] Thrombocytopenia after second exposure to abciximab is caused by antibodies that recognize abciximab-coated platelets [J].

Curtis, BR ;

Swyers, J ;

Divgi, A ;

McFarland, JG ;

Aster, RH .

BLOOD, 2002, 99 (06) :2054-2059

[10] Final results of the ReoPro Readministration Registry [J].

Dery, JP ;

Braden, GA ;

Lincoff, AM ;

Kereiakes, DJ ;

Browne, K ;

Little, T ;

George, BS ;

Sane, DC ;

Cines, DB ;

Effron, MB ;

Mascelli, MA ;

Langrall, MA ;

Damaraju, L ;

Barnathan, ES ;

Tcheng, JE .

AMERICAN JOURNAL OF CARDIOLOGY, 2004, 93 (08) :979-984

← 1 2 →